These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 11212247)

  • 1. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
    J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
    Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
    Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.
    Apostolopoulou K; Pateras IS; Evangelou K; Tsantoulis PK; Liontos M; Kittas C; Tiniakos DG; Kotsinas A; Cordon-Cardo C; Gorgoulis VG
    J Pathol; 2007 Nov; 213(3):294-302. PubMed ID: 17907153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
    Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
    Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation.
    Marchetti A; Doglioni C; Barbareschi M; Buttitta F; Pellegrini S; Bertacca G; Chella A; Merlo G; Angeletti CA; Dalla Palma P; Bevilacqua G
    Oncogene; 1996 Mar; 12(6):1319-24. PubMed ID: 8649834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
    Shabnam MS; Srinivasan R; Wali A; Majumdar S; Joshi K; Behera D
    Lung Cancer; 2004 Aug; 45(2):181-8. PubMed ID: 15246189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
    Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
    Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
    Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
    Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.